Physicochemical Properties
| Molecular Formula | C25H26CLN5O2.8/5HCL |
| Molecular Weight | 522.31 |
| Related CAS # | OTS186935;2093400-18-9;OTS186935 trihydrochloride;2093401-85-3 |
| Appearance | Light yellow to yellow solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | SUV39H2/KMT1B |
| ln Vitro | At an IC50 of 0.67 μM, OTS186935 hydrochloride inhibits the proliferation of A549 cells[1]. |
| ln Vivo | In xenograft models created from human cancer cell lines, OTS186935 hydrochloride (10 mg/kg or 25 mg/kg; intravenously; once daily for 14 days) shows growth inhibition [1]. |
| Animal Protocol |
Animal/Disease Models: Female NOD.CB17-Prkdcscid/J mice (bearing MDA-MB-231 cells )[1] Doses: 10 mg/kg Route of Administration: intravenously (iv); one time/day for 14 days Experimental Results: Tumor growth inhibition of 42.6% on day 14 . Animal/Disease Models: Female BALB/cAJcl-nu/nu (nude) mice (bearing A549 cells)[1] Doses: 25 mg/kg Route of Administration: intravenously (iv); one time/day for 14 days Experimental Results: Yielded a tumor growth inhibition of 60.8% without significant body weight loss or toxicity. |
| References |
[1]. Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. Oncotarget. 2018 Aug 7;9(61):31820-31831. |
Solubility Data
| Solubility (In Vitro) |
H2O :~50 mg/mL (~95.73 mM) DMSO :~25 mg/mL (~47.86 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (3.98 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 100 mg/mL (191.46 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9146 mL | 9.5729 mL | 19.1457 mL | |
| 5 mM | 0.3829 mL | 1.9146 mL | 3.8291 mL | |
| 10 mM | 0.1915 mL | 0.9573 mL | 1.9146 mL |